Irish researches find potential therapy for wet AMD

Article

Scientists at Trinity College Dublin have found that a component of the immune system suppresses the production of damaging blood vessels behind the retina, which could aid in the treatment of wet age-related macular degeneration, according to research recently published in Science Translational Medicine.

Dublin, Ireland-Scientists at Trinity College Dublin have found that a component of the immune system suppresses the production of damaging blood vessels behind the retina, which could aid in the treatment of wet age-related macular degeneration, according to research recently published in Science Translational Medicine

In pre-clinical models, the component, IL-18, could be administered in a non-invasive way, which the researchers say could be a major improvement to the current therapeutic options available to AMD patients.

“We were initially concerned that IL-18 might cause damage to the sensitive cells of the retina, because it is typically linked to inflammation. But, surprisingly, we found that low doses had no adverse effects on the retina and yet still suppressed abnormal blood vessel growth,” says Sarah Doyle, assistant professor of immunology at Trinity.

Current treatment options for wet AMD include regular injections of antibiotics mad directly into the eye to prevent vascular endothelial growth factor (VEGF) toward the end stages of the disease. Researchers found that IL-18 directly inhibits VEGF production, and that it can work as effectively as the current treatment when administered via a non-invasive intravenous injection in pre-clinical settings. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.